お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:注目市場の分析:肥満
市場調査レポート
商品コード
917495

注目市場の分析:肥満

Market Spotlight: Obesity

出版日: | 発行: Datamonitor Healthcare | ページ情報: 英文 52 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.33円
注目市場の分析:肥満
出版日: 2021年02月22日
発行: Datamonitor Healthcare
ページ情報: 英文 52 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、肥満治療市場について分析し、疾患の概要や患者数の推移・見通し、現段階での主な治療法、規制環境と近年の主な出来事、現在開発中の治験の進行状況と上市スケジュール、主な治療薬の市場動向見通し、資本取引の動きなどを調査しております。

概要

要点

疾患の背景事情

治療法

  • 医薬品
  • 手術

疫学

上市済み医薬品

パイプライン薬

最新イベント・アナリストの見解

近い将来のイベント

規制関連の主なイベント

成功の可能性

ライセンス契約・資産買収取引

母体特許

収益機会

治験情勢

  • スポンサー数:ステータス別
  • スポンサー数:フェーズ (相) 別
  • 近年の動向

関連分析

  • 処方薬の情報

付録

目次
Product Code: DMKC0199735

This Market Spotlight report covers the Obesity market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

Datamonitor Healthcare estimates that in 2017, there were approximately 681.3 million prevalent cases of obesity in adults (aged 20+ years) worldwide, and expects that number to increase to 762.9 million prevalent cases by 2026.

In the same year, Datamonitor Healthcare estimates that there were 126.6 million prevalent cases of obesity in children and adolescents (aged 5-19 years) worldwide, and expects that number to increase to 134.0 million prevalent cases by 2026.

Prevalence proportions are highest in Northern America and lowest in Asia. The approved drugs in the obesity space target gastric lipase, dopamine, norepinephrine (noradrenaline), dopamine reuptake, norepinephrine (noradrenaline) reuptake/transporter, opioid receptors, GABA-A receptor, and glucagon-like peptide-1 (GLP-1) receptor. The majority of marketed drugs are administered via the oral route, with one product being available in a subcutaneous formulation.

The majority of industry-sponsored drugs in active clinical development for obesity are in Phase I, with only one drug in Phase III and one in the NDA/BLA stage.

Therapies in development for obesity focus on a wide variety of targets, with the subcutaneous route being the most common method of delivery.

High-impact upcoming events for drugs in the obesity space comprise a decentralized EU approval and an estimated EU patent expiration for Qsymia; an expected supplemental CHMP opinion and a PDUFA date for Ozempic; and topline Phase III trial results for tirzepatide.

The overall likelihood of approval of a Phase I obesity asset is 2.5%, and the average probability a drug advances from Phase III is 66.7%. Drugs, on average, take 8.5 years from Phase I to approval, compared to 9.1 years in the overall metabolic space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for obesity have been in the early and midphases of development, with 66% of trials in Phase I-II, and 34% in Phase III-IV.

The US has a substantial lead in the number of obesity clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.

Clinical trial activity in the obesity space is dominated by completed trials. Novo Nordisk has the highest number of completed clinical trials for obesity, with 82 trials.

Novo Nordisk leads industry sponsors with the highest overall number of clinical trials for obesity, followed by AstraZeneca.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Medications
  • Surgery

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Tesomet for Obesity (November 23, 2020)
  • AM833 for Obesity (June 18, 2020)
  • Ozempic for Obesity (June 12, 2020)
  • Ozempic for Obesity (June 4, 2020)
  • Ozempic for Obesity (May 13, 2020)
  • Tesomet for Obesity (April 22, 2020)
  • Efpeglenatide for Obesity (December 10, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Review Vouchers: Danyelza, Imcivree Earn; Novo Nordisk Spends
  • Rhythm's Setmelanotide Loses Fast-Track Status In Europe
  • MAAs Under Review/Rhythm Files Setmelanotide
  • EMA Considers Fast-Tracking Rhythm's Insatiable Hunger and Obesity Disorders Drug
  • Three Fast Track Drugs Stand Out In Flurry Of Submissions
  • FDA Requests Belviq Be Pulled From The US Market Due To Cancer Risk

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Senda Teams With Nestle Nutritional Health For Metabolic Conditions
  • CMS Pays $35m For China Rights To Gelesis Obesity Therapy

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of obesity in adults, 2017-26
  • Figure 2: Overview of pipeline drugs for obesity in the US
  • Figure 3: Pipeline drugs for obesity, by company
  • Figure 4: Pipeline drugs for obesity, by drug type
  • Figure 5: Pipeline drugs for obesity, by classification
  • Figure 6: Tesomet for Obesity (November 23, 2020): Phase IIa - Hypothalamic Obesity (Denmark)
  • Figure 7: AM833 for Obesity (June 18, 2020): Phase I - w/Semaglutide
  • Figure 8: AM833 for Obesity (June 18, 2020): Phase II - 4433
  • Figure 9: Ozempic for Obesity (June 12, 2020): Phase IIIa - STEP 2 (Overweight/obese diabetics), Phase IIIa - STEP 3 (Maximizing Weight Loss)
  • Figure 10: Ozempic for Obesity (June 4, 2020): Phase IIIa - STEP 1 (Weight Loss)
  • Figure 11: Ozempic for Obesity (May 13, 2020): Phase IIIa - STEP 4 (Maintained Weight Loss)
  • Figure 12: Tesomet for Obesity (April 22, 2020): Phase IIa - Hypothalamic Obesity (Denmark)
  • Figure 13: Key upcoming events in obesity
  • Figure 14: Probability of success in the obesity pipeline
  • Figure 15: Clinical trials in obesity
  • Figure 16: Top 10 drugs for clinical trials in obesity
  • Figure 17: Top 10 companies for clinical trials in obesity
  • Figure 18: Trial locations in obesity
  • Figure 19: Obesity trials status
  • Figure 20: Obesity trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of obesity in adults, 2017-26
  • Table 2: Prevalent cases of morbid obesity in adults, 2017-26
  • Table 3: Prevalent cases of obesity in children and adolescents, 2017-26
  • Table 4: Prevalence proportions of obesity and morbid obesity, 2017
  • Table 5: Marketed drugs for obesity
  • Table 6: Pipeline drugs for obesity in the US
  • Table 7: Tesomet for Obesity (November 23, 2020)
  • Table 8: AM833 for Obesity (June 18, 2020)
  • Table 9: Ozempic for Obesity (June 12, 2020)
  • Table 10: Ozempic for Obesity (June 4, 2020)
  • Table 11: Ozempic for Obesity (May 13, 2020)
  • Table 12: Tesomet for Obesity (April 22, 2020)
  • Table 13: Efpeglenatide for Obesity (December 10, 2019)
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.